Evogene (EVGN) Expected to Announce Earnings on Thursday

Evogene (NASDAQ:EVGN) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $0.2750 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:00 AM ET.

Evogene Trading Up 4.6%

Shares of NASDAQ:EVGN opened at $0.88 on Thursday. The company has a 50-day moving average price of $1.02 and a 200-day moving average price of $1.15. The company has a market cap of $4.71 million, a price-to-earnings ratio of -1.75 and a beta of 1.35. Evogene has a 12 month low of $0.81 and a 12 month high of $2.42.

Hedge Funds Weigh In On Evogene

Several hedge funds have recently made changes to their positions in the business. XTX Topco Ltd bought a new position in shares of Evogene during the fourth quarter valued at approximately $25,000. Jane Street Group LLC increased its position in Evogene by 58.0% during the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares during the period. Finally, Citadel Advisors LLC increased its position in Evogene by 169.4% during the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 36,206 shares during the period. 10.40% of the stock is owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.